Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:SCLN's Cash to Debt is ranked higher than
99% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. NAS:SCLN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:SCLN' s Cash to Debt Range Over the Past 10 Years
Min: 2.83  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.90
NAS:SCLN's Equity to Asset is ranked higher than
93% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:SCLN: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
NAS:SCLN' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.83 Max: 0.91
Current: 0.9
0.52
0.91
Interest Coverage No Debt
NAS:SCLN's Interest Coverage is ranked higher than
98% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. NAS:SCLN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:SCLN' s Interest Coverage Range Over the Past 10 Years
Min: 34.65  Med: 114.84 Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 16.29
M-Score: -2.34
WACC vs ROIC
11.83%
52.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.22
NAS:SCLN's Operating margin (%) is ranked higher than
88% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. NAS:SCLN: 25.22 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:SCLN' s Operating margin (%) Range Over the Past 10 Years
Min: -30.48  Med: 12.8 Max: 26.31
Current: 25.22
-30.48
26.31
Net-margin (%) 24.02
NAS:SCLN's Net-margin (%) is ranked higher than
91% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. NAS:SCLN: 24.02 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:SCLN' s Net-margin (%) Range Over the Past 10 Years
Min: -26.84  Med: 12.57 Max: 24.77
Current: 24.02
-26.84
24.77
ROE (%) 21.78
NAS:SCLN's ROE (%) is ranked higher than
86% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. NAS:SCLN: 21.78 )
Ranked among companies with meaningful ROE (%) only.
NAS:SCLN' s ROE (%) Range Over the Past 10 Years
Min: -19.53  Med: 12.14 Max: 30.21
Current: 21.78
-19.53
30.21
ROA (%) 18.62
NAS:SCLN's ROA (%) is ranked higher than
91% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NAS:SCLN: 18.62 )
Ranked among companies with meaningful ROA (%) only.
NAS:SCLN' s ROA (%) Range Over the Past 10 Years
Min: -16.41  Med: 10.07 Max: 25.6
Current: 18.62
-16.41
25.6
ROC (Joel Greenblatt) (%) 151.64
NAS:SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. NAS:SCLN: 151.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:SCLN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -86.48  Med: 60.84 Max: 151.64
Current: 151.64
-86.48
151.64
Revenue Growth (3Y)(%) 4.10
NAS:SCLN's Revenue Growth (3Y)(%) is ranked lower than
55% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NAS:SCLN: 4.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:SCLN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.8  Med: 16.9 Max: 123.1
Current: 4.1
-4.8
123.1
EBITDA Growth (3Y)(%) 51.80
NAS:SCLN's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. NAS:SCLN: 51.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:SCLN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.9  Med: -8.05 Max: 51.8
Current: 51.8
-53.9
51.8
EPS Growth (3Y)(%) 51.80
NAS:SCLN's EPS Growth (3Y)(%) is ranked higher than
89% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:SCLN: 51.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:SCLN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.4  Med: -5.15 Max: 132.1
Current: 51.8
-59.4
132.1
» NAS:SCLN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

SCLN Guru Trades in Q3 2015

Ken Fisher 398,426 sh (New)
Paul Tudor Jones 85,471 sh (+201.91%)
Chuck Royce 5,000 sh (unchged)
Jim Simons 443,500 sh (-35.88%)
» More
Q4 2015

SCLN Guru Trades in Q4 2015

Jim Simons 583,080 sh (+31.47%)
Ken Fisher 484,848 sh (+21.69%)
Chuck Royce Sold Out
Paul Tudor Jones 67,578 sh (-20.93%)
» More
Q1 2016

SCLN Guru Trades in Q1 2016

George Soros 32,100 sh (New)
Jim Simons 932,300 sh (+59.89%)
Paul Tudor Jones 70,121 sh (+3.76%)
Ken Fisher 459,607 sh (-5.21%)
» More
Q2 2016

SCLN Guru Trades in Q2 2016

Jim Simons 1,161,700 sh (+24.61%)
Paul Tudor Jones Sold Out
George Soros Sold Out
Ken Fisher 298,014 sh (-35.16%)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:FLXN, NAS:ACET, NAS:LBIO, NAS:SCMP, OTCPK:LPCUF, NAS:ADMS, OTCPK:EVOTF, NAS:COLL, NAS:HRTX, NAS:ARLZ, NAS:SGNT, NAS:KPTI, NAS:RIGL, OTCPK:TWMJF, NAS:AQXP, NAS:SNDX, NAS:DRRX, NAS:MNTA, NAS:AGRX, OTCPK:ORXOY » details
Traded in other countries:SPJ.Germany,
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.

SciClone Pharmaceuticals Inc is a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 7 partnered and in-licensed products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. SPIL orders ZADAXIN from its European manufacturer and contracts with a third party for the storage of its finished goods inventory at warehousing facilities in Hong Kong. SPIL then distributes its product from these warehousing facilities based on purchase orders from its customers. ZADAXIN is manufactured in Europe by third parties under exclusive contract manufacturing and supply agreements. Its competitors include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.

Ratios

vs
industry
vs
history
P/E(ttm) 14.13
SCLN's P/E(ttm) is ranked higher than
83% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.52 vs. SCLN: 14.13 )
Ranked among companies with meaningful P/E(ttm) only.
SCLN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.32  Med: 17.03 Max: 400
Current: 14.13
6.32
400
PE(NRI) 14.13
SCLN's PE(NRI) is ranked higher than
83% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.50 vs. SCLN: 14.13 )
Ranked among companies with meaningful PE(NRI) only.
SCLN' s PE(NRI) Range Over the Past 10 Years
Min: 6.32  Med: 17.03 Max: 280
Current: 14.13
6.32
280
Price/Owner Earnings (ttm) 19.04
SCLN's Price/Owner Earnings (ttm) is ranked higher than
75% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.08 vs. SCLN: 19.04 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SCLN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.4  Med: 17.73 Max: 83.89
Current: 19.04
6.4
83.89
P/B 2.68
SCLN's P/B is ranked higher than
56% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. SCLN: 2.68 )
Ranked among companies with meaningful P/B only.
SCLN' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 2.12 Max: 4.91
Current: 2.68
0.82
4.91
P/S 3.38
SCLN's P/S is ranked lower than
57% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SCLN: 3.38 )
Ranked among companies with meaningful P/S only.
SCLN' s P/S Range Over the Past 10 Years
Min: 0.67  Med: 2.41 Max: 9.4
Current: 3.38
0.67
9.4
PFCF 16.08
SCLN's PFCF is ranked higher than
70% of the 193 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. SCLN: 16.08 )
Ranked among companies with meaningful PFCF only.
SCLN' s PFCF Range Over the Past 10 Years
Min: 3.77  Med: 15.45 Max: 458
Current: 16.08
3.77
458
POCF 15.67
SCLN's POCF is ranked higher than
55% of the 256 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. SCLN: 15.67 )
Ranked among companies with meaningful POCF only.
SCLN' s POCF Range Over the Past 10 Years
Min: 3.71  Med: 14.67 Max: 218.1
Current: 15.67
3.71
218.1
EV-to-EBIT 9.97
SCLN's EV-to-EBIT is ranked higher than
84% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. SCLN: 9.97 )
Ranked among companies with meaningful EV-to-EBIT only.
SCLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.9  Med: 6.8 Max: 202.4
Current: 9.97
-21.9
202.4
EV-to-EBITDA 9.76
SCLN's EV-to-EBITDA is ranked higher than
76% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. SCLN: 9.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCLN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.8  Med: 6.45 Max: 51.1
Current: 9.76
-22.8
51.1
PEG 4.21
SCLN's PEG is ranked lower than
70% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. SCLN: 4.21 )
Ranked among companies with meaningful PEG only.
SCLN' s PEG Range Over the Past 10 Years
Min: 0.99  Med: 2.84 Max: 6.94
Current: 4.21
0.99
6.94
Shiller P/E 40.53
SCLN's Shiller P/E is ranked higher than
62% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.59 vs. SCLN: 40.53 )
Ranked among companies with meaningful Shiller P/E only.
SCLN' s Shiller P/E Range Over the Past 10 Years
Min: 32.57  Med: 55.06 Max: 590
Current: 40.53
32.57
590
Current Ratio 7.84
SCLN's Current Ratio is ranked higher than
87% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. SCLN: 7.84 )
Ranked among companies with meaningful Current Ratio only.
SCLN' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 5.72 Max: 12.05
Current: 7.84
1.32
12.05
Quick Ratio 7.31
SCLN's Quick Ratio is ranked higher than
87% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SCLN: 7.31 )
Ranked among companies with meaningful Quick Ratio only.
SCLN' s Quick Ratio Range Over the Past 10 Years
Min: 1.05  Med: 5.24 Max: 11.4
Current: 7.31
1.05
11.4
Days Inventory 181.20
SCLN's Days Inventory is ranked lower than
77% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. SCLN: 181.20 )
Ranked among companies with meaningful Days Inventory only.
SCLN' s Days Inventory Range Over the Past 10 Years
Min: 171.31  Med: 206 Max: 265.07
Current: 181.2
171.31
265.07
Days Sales Outstanding 80.17
SCLN's Days Sales Outstanding is ranked lower than
52% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. SCLN: 80.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.17  Med: 108.44 Max: 148.37
Current: 80.17
80.17
148.37
Days Payable 40.22
SCLN's Days Payable is ranked lower than
77% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. SCLN: 40.22 )
Ranked among companies with meaningful Days Payable only.
SCLN' s Days Payable Range Over the Past 10 Years
Min: 40.22  Med: 94.63 Max: 159.4
Current: 40.22
40.22
159.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.10
SCLN's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SCLN: 3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCLN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -4.9 Max: 4.8
Current: 3.1
-22.9
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.45
SCLN's Price/Net Cash is ranked higher than
71% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. SCLN: 5.45 )
Ranked among companies with meaningful Price/Net Cash only.
SCLN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.06  Med: 5.51 Max: 344
Current: 5.45
2.06
344
Price/Net Current Asset Value 3.57
SCLN's Price/Net Current Asset Value is ranked higher than
78% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. SCLN: 3.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SCLN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.93  Med: 3.78 Max: 53.57
Current: 3.57
0.93
53.57
Price/Tangible Book 3.25
SCLN's Price/Tangible Book is ranked higher than
56% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SCLN: 3.25 )
Ranked among companies with meaningful Price/Tangible Book only.
SCLN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 3.47 Max: 17.78
Current: 3.25
0.84
17.78
Price/Projected FCF 1.27
SCLN's Price/Projected FCF is ranked higher than
79% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. SCLN: 1.27 )
Ranked among companies with meaningful Price/Projected FCF only.
SCLN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.16 Max: 6.05
Current: 1.27
0.7
6.05
Price/Median PS Value 1.41
SCLN's Price/Median PS Value is ranked lower than
64% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. SCLN: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
SCLN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.57 Max: 97.5
Current: 1.41
0.26
97.5
Price/Graham Number 1.43
SCLN's Price/Graham Number is ranked higher than
70% of the 400 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SCLN: 1.43 )
Ranked among companies with meaningful Price/Graham Number only.
SCLN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.68  Med: 1.53 Max: 4.46
Current: 1.43
0.68
4.46
Earnings Yield (Greenblatt) (%) 10.06
SCLN's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SCLN: 10.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCLN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 9.8 Max: 489.7
Current: 10.06
0.5
489.7

More Statistics

Revenue (TTM) (Mil) $161.2
EPS (TTM) $ 0.74
Beta1.36
Short Percentage of Float6.02%
52-Week Range $6.47 - 15.03
Shares Outstanding (Mil)49.94
» More Articles for NAS:SCLN

Headlines

Articles On GuruFocus.com
Profits in Motion: SciClone Pharmaceuticals (SCLN), Omega Protein (OME), Zoe's Kitchen (ZOES) Mar 12 2015 
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
SciClone Pharmaceuticals Inc. (SCLN) CEO Friedhelm Blobel buys 10,000 Shares May 26 2009 
SciClone Pharmaceuticals Inc. (SCLN) CFO Gary Titus buys 4,625 Shares May 26 2009 

More From Other Websites
SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market Sep 26 2016
Soligenix (SNGX) and SciClone (SCLN) Establish Regional Licensing Agreement for SGX942, a Novel... Sep 12 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate... Sep 12 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate... Sep 12 2016
SciClone To Present At Two Investor Conferences In September 2016 Sep 01 2016
ETF’s with exposure to SciClone Pharmaceuticals, Inc. : August 31, 2016 Aug 31 2016
Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 million of Stocks Aug 18 2016
SCICLONE PHARMACEUTICALS INC Financials Aug 18 2016
ETF’s with exposure to SciClone Pharmaceuticals, Inc. : August 16, 2016 Aug 16 2016
SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15,... Aug 15 2016
Are High Composite Ratings An Automatic 'Buy' Signal? No. Here's Why Aug 10 2016
SciClone posts 2Q profit Aug 09 2016
SciClone posts 2Q profit Aug 09 2016
SciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016 Aug 09 2016
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 09 2016
SciClone Reports Second Quarter 2016 Financial Results Aug 09 2016
Q2 2016 SciClone Pharmaceuticals Inc Earnings Release - Time Not Supplied Aug 09 2016
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits Aug 03 2016
SciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016 Jul 28 2016
ETF’s with exposure to SciClone Pharmaceuticals, Inc. : July 20, 2016 Jul 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)